儿童RUNX1-FPDMM患者血液系统恶性肿瘤特征研究
该研究基于美国NIH RUNX1自然史研究,分析了213例RUNX1-FPDMM患者的临床与实验室特征。儿童患者(<19岁)较成人出血频率更低,18岁前累积恶性血液病发病率为7.3%,是普通人群的57.7倍;儿童患者恶性血液病以髓系为主,且体细胞突变较少而染色体改变较多。建议新诊断后无论年龄均行级联RUNX1检测,并定期监测血常规与骨髓活检。
要点
- 儿童RUNX1-FPDMM患者18岁前累积恶性血液病发病率为7.3%,是普通人群的57.7倍。
- 儿童患者恶性血液病谱系较广但以髓系为主(占62%),较成人更少伴多体细胞突变。
- 建议新诊断后无论年龄均行级联RUNX1检测,并每季度血常规、每年骨髓活检监测。
核心结论
- 儿童RUNX1-FPDMM患者恶性血液病风险显著高于普通人群,建议新诊断后无论年龄均行级联RUNX1检测。
研究设计与样本
- 基于美国NIH RUNX1自然史研究(NCT03854318)的队列分析,纳入213例RUNX1-FPDMM患者,其中儿童(<19岁)与成人对比。
主要发现
- 儿童患者血小板计数为131 ± 49 ×103/μL,成人314 ± 55 ×103/μL;儿童嗜酸性粒细胞372 ± 244/μL,成人165 ± 100/μL。
- 儿童恶性血液病髓系占62%,普通儿童人群为24%;儿童5岁前发生恶性血液病风险是范可尼贫血患者的3.4倍。
- 儿童患者恶性血液病伴多体细胞突变者22%,成人67%;伴染色体改变者67%,成人47%。
临床怎么用
- 新诊断RUNX1-FPDMM后无论年龄均推荐行级联RUNX1检测。
- 儿童患者确诊后临床允许时行基线骨髓活检及外周血评估。
- 建议每季度血常规、每年骨髓活检以监测病情变化及恶性转化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deleterious germ line RUNX1 variants cause familial platelet disorder with associated myeloid malignancy (FPDMM), characterized by thrombocytopenia, platelet dysfunction, and predisposition to hematologic malignancies (HM). We examined clinical and laboratory findings of pediatric (<19 years) patients with RUNX1-FPDMM enrolled in the National Institutes of Health RUNX1 Natural History Study. Pediatric patients have thrombocytopenia (131 ± 49 ×103/μL vs 314 ± 55 ×103/μL) and mild eosinophilia (372 ± 244/μL vs 165 ± 100/μL) similar to adults. Abnormal bleeding is less frequent in children than adults (32% vs 42%). Of 213 patients with RUNX1-FPDMM, 31 developed HM (13 pediatric, 19 adult; 1 had second malignancy). Lifetime HM risk is 42% (26%-55%). Median age of HM diagnosis is 36 years (range, 1-74). Pediatric patients have a 7.3% (3.5%-11%) cumulative incidence by age 18 years, 57.7-fold (27.7-86.6) higher than the general population, and are 3.4-fold more likely to develop HM by age 5 years than patients with Fanconi anemia. Unlike adult patients whose HM were all myeloid, pediatric patients develop a spectrum of HM but with a myeloid excess compared with the general pediatric population (62% vs 24%). Pediatric RUNX1-FPDMM HM is less likely than adult to have multiple somatic mutations (22% vs 67%), but more likely to have chromosome changes (67% vs 47%). We recommend prompt, universal cascade RUNX1 testing following a new diagnosis, regardless of age. Upon diagnosis, management of pediatric RUNX1-FPDMM should include a baseline bone marrow biopsy, once clinically acceptable, and peripheral blood evaluations. We recommend routine monitoring with quarterly blood counts and annual biopsy to monitor for changes and HM transformation. This trial was registered www.clinicaltrials.gov as #NCT03854318.
引用
- Kajdic A, Deuitch NT, Bresciani E, et al. Hematologic malignancies in pediatric patients with RUNX1-familial platelet disorder with associated myeloid malignancy. Blood Adv. 2026. PMID: 41616279. doi:10.1182/bloodadvances.2025017808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。